Legend Biotech EBITDA 2019-2021 | LEGN

Legend Biotech annual and quarterly EBITDA history from 2019 to 2021. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Legend Biotech EBITDA for the quarter ending December 31, 2021 was $-0.120B, a 107.18% increase year-over-year.
  • Legend Biotech EBITDA for the twelve months ending December 31, 2021 was $-0.379B, a 69.68% increase year-over-year.
  • Legend Biotech 2021 annual EBITDA was $-0.365B, a 71.05% increase from 2020.
  • Legend Biotech 2020 annual EBITDA was $-0.213B, a 70.95% increase from 2019.
  • Legend Biotech 2019 annual EBITDA was $-0.125B, a 83915.44% decline from 2018.
Legend Biotech Annual EBITDA
(Millions of US $)
2021 $-365
2020 $-213
2019 $-125
2018 $0
Legend Biotech Quarterly EBITDA
(Millions of US $)
2021-12-31 $-120
2021-09-30 $-89
2021-06-30 $-90
2021-03-31 $-81
2020-12-31 $-58
2020-09-30 $-67
2020-06-30 $-55
2020-03-31 $-44
2019-12-31 $-62
2019-09-30 $-28
2019-06-30 $-28
2019-03-31 $-12
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.274B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00